Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report
- PMID: 20016531
- PMCID: PMC2906139
- DOI: 10.1038/leu.2009.262
Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report
Abstract
The Children's Cancer Group enrolled 13 298 young people age <21 years on 1 of 16 protocols between 1983 and 2002. Outcomes were examined in three time periods, 1983-1988, 1989-1995, 1996-2002. Over the three intervals, 10-year event-free survival (EFS) for Rome/National Cancer Institute standard risk (SR) and higher risk (HR) B-precursor patients was 68 and 58%, 77 and 63%, and 78 and 67%, respectively, whereas for SR and HR T-cell patients, EFS was 65 and 56%, 78 and 68%, and 70 and 72%, respectively. Five-year EFS for infants was 36, 38, and 43%, respectively. Seminal randomized studies led to a number of important findings. Stronger post-induction intensification improved outcome for both SR and HR patients. With improved systemic therapy, additional intrathecal (IT) methotrexate effectively replaced cranial radiation. For SR patients receiving three-drug induction, iso-toxic substitution of dexamethasone for prednisone improved EFS. Pegylated asparaginase safely and effectively replaced native asparaginase. Thus, rational therapy modifications yielded better outcomes for both SR and HR patients. These trials provide the platforms for current Children's Oncology Group trials.
Figures
Similar articles
-
Long-term results of Tokyo Children's Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984-1999.Leukemia. 2010 Feb;24(2):383-96. doi: 10.1038/leu.2009.260. Epub 2009 Dec 24. Leukemia. 2010. PMID: 20033052 Clinical Trial.
-
Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group.Leukemia. 2010 Feb;24(2):355-70. doi: 10.1038/leu.2009.261. Epub 2009 Dec 17. Leukemia. 2010. PMID: 20016527 Free PMC article. Clinical Trial.
-
Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia.Leukemia. 2010 Feb;24(2):397-405. doi: 10.1038/leu.2009.248. Epub 2009 Dec 17. Leukemia. 2010. PMID: 20016538 Clinical Trial.
-
Long-term outcome of treatment with protocols AL841, AL851, and ALHR88 in children with acute lymphoblastic leukemia: results obtained by the Kyushu-Yamaguchi Children's Cancer Study Group.Int J Hematol. 2001 Apr;73(3):369-77. doi: 10.1007/BF02981964. Int J Hematol. 2001. PMID: 11345205 Review.
-
More is better! Update of Dana-Farber Cancer Institute/Children's Hospital childhood acute lymphoblastic leukemia trials.Haematol Blood Transfus. 1990;33:459-66. doi: 10.1007/978-3-642-74643-7_83. Haematol Blood Transfus. 1990. PMID: 2182437 Review.
Cited by
-
Prediction of Response to FDA-Approved Targeted Therapy and Immunotherapy in Acute Lymphoblastic Leukemia (ALL).Curr Treat Options Oncol. 2024 Sep;25(9):1163-1183. doi: 10.1007/s11864-024-01237-w. Epub 2024 Aug 5. Curr Treat Options Oncol. 2024. PMID: 39102166 Review.
-
Genetic Factors and Long-term Treatment-Related Neurocognitive Deficits, Anxiety, and Depression in Childhood Leukemia Survivors: An Exome-Wide Association Study.Cancer Epidemiol Biomarkers Prev. 2024 Feb 6;33(2):234-243. doi: 10.1158/1055-9965.EPI-23-0634. Cancer Epidemiol Biomarkers Prev. 2024. PMID: 38051303 Free PMC article.
-
Comprehensive characterization of patient-derived xenograft models of pediatric leukemia.iScience. 2023 Oct 10;26(11):108171. doi: 10.1016/j.isci.2023.108171. eCollection 2023 Nov 17. iScience. 2023. PMID: 37915590 Free PMC article.
-
Constitutively Synergistic Multiagent Drug Formulations Targeting MERTK, FLT3, and BCL-2 for Treatment of AML.Pharm Res. 2023 Sep;40(9):2133-2146. doi: 10.1007/s11095-023-03596-9. Epub 2023 Sep 13. Pharm Res. 2023. PMID: 37704893
-
Pharmacologic Inhibition of NT5C2 Reverses Genetic and Nongenetic Drivers of 6-MP Resistance in Acute Lymphoblastic Leukemia.Cancer Discov. 2022 Nov 2;12(11):2646-2665. doi: 10.1158/2159-8290.CD-22-0010. Cancer Discov. 2022. PMID: 35984649 Free PMC article.
References
-
- Pinkel D, Simone J, Hustu HO, Aur RJ. Nine years’ experience with “total therapy” of childhood acute lymphocytic leukemia. Pediatr. 1972;50(2):246–251. - PubMed
-
- Henze G, Langermann HJ, Bramswig J, Breu H, Gadner H, Schellong G, Welte K, Riehm H. The BFM 76/79 acute lymphoblastic leukemia therapy study (author’s transl) Klin Padiatr. 1981;193(3):145–154. - PubMed
-
- Bleyer WA, Coccia PF, Sather HN, Level C, Lukens J, Niebrugge DJ, Siegel S, Littman PS, Leikin SL, Miller DR, et al. Reduction in central nervous system leukemia with a pharmacokinetically derived IT methotrexate dosage regimen. J Clin Oncol. 1983;1(5):317–325. - PubMed
-
- Miller DR, Leikin S, Albo V, Sather H, Karon M, Hammond D. Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG-141. A report from the Children’s Cancer Study Group. Cancer. 1983;51(6):1041–1049. - PubMed
-
- Bleyer WA, Sather HN, Nickerson HJ, Coccia PF, Finklestein JZ, Miller DR, et al. Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: a report of the CCG-161 study by the Childrens Cancer Study Group. J Clin Oncol. 1991;9(6):1012–1021. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials